Beren Therapeutics
Summary active Updated Jun 13, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Beren Therapeutics P.B.C. is a Thousand Oaks, California-based public benefit company developing cyclodextrin-based therapeutics for cholesterol trafficking disorders 12. The company is the parent of Mandos LLC and is led by Founder and CEO Jason Camm 1. Its lead candidate is adrabetadex for infantile-onset Niemann-Pick disease Type C (I-NPC), a rare and ultimately fatal lysosomal storage disorder; the FDA accepted Beren’s New Drug Application for adrabetadex in February 2026 under Priority Review, with a target action decision on November 17, 2026 13.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-10 | Equity + Debt | $300M total | Wellington Partners, JIC Venture Growth Investments, Founders Fund, Narya Capital, Eisai Co. (equity); Hercules Capital (debt + royalty) | (select institutional investors) 124 |
The $300M financing comprises a $135M equity round led by Wellington Partners, JIC Venture Growth Investments, Founders Fund, Narya Capital, and Eisai Co., alongside up to $165M in a strategic financing facility from Hercules Capital (comprising $110M senior-secured debt and $55M royalty financing) 12. Capital supports preparation for potential commercialization of adrabetadex and long-term care initiatives for the rare disease community 1.
What Investors Say
No independently sourced investor quotes available at this time.
What Founders Say
No independently sourced founder quotes available at this time.
Sources
-
Business Wire, “Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C,” June 10, 2026. https://www.businesswire.com/news/home/20260610248466/en/Beren-Therapeutics-Secures-$300M-Financing-to-Support-the-Potential-Commercial-Launch-of-Adrabetadex-and-Long-Term-Care-Initiatives-for-Infantile-Onset-Niemann-Pick-Disease-Type-C↩↩↩↩↩↩
-
Finsmes, “Beren Therapeutics Raises $300M in Combined Equity and Debt Financing,” June 2026. https://www.finsmes.com/2026/06/beren-therapeutics-raises-300m-in-combined-equity-and-debt-financing.html↩↩↩
-
GuruFocus, “Beren Therapeutics Secures $300M Financing with HTGC Support,” June 2026. https://www.gurufocus.com/news/8910065/beren-therapeutics-secures-300m-financing-with-htgc-support↩
-
Yahoo Finance via Business Wire, “Beren Therapeutics Secures $300M Financing,” June 10, 2026. https://finance.yahoo.com/sectors/healthcare/articles/beren-therapeutics-secures-300m-financing-130000714.html↩